Sanofi Acquires Blueprint Medicines in \$9.5 Billion Deal to Bolster Immunology Portfolio

In a significant move to enhance its immunology portfolio, French pharmaceutical giant Sanofi has agreed to acquire U.S.-based biopharmaceutical company Blueprint Medicines. The transaction, valued at approximately \$9.5 billion on a fully diluted basis, includes a cash payment of \$129.00 per share and contingent value rights (CVRs) offering up to \$6.00 per share based on future regulatory milestones for BLU-808.

Blueprint Medicines specializes in treatments for systemic mastocytosis, a rare immunological disorder characterized by the accumulation of aberrant mast cells in various organs. The acquisition brings Ayvakit (avapritinib), the only approved therapy for both advanced and indolent forms of systemic mastocytosis, into Sanofi's portfolio. Additionally, Sanofi gains access to promising pipeline candidates, including elenestinib and BLU-808, which have potential applications across a range of immunological diseases.

Sanofi CEO Paul Hudson stated that the acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company".

The deal is expected to close in the third quarter of 2025, pending customary closing conditions. Sanofi plans to finance the acquisition through a combination of cash and new debt.

This acquisition aligns with Sanofi's strategic focus on expanding its immunology and rare disease offerings, following recent deals such as the acquisitions of Vigil Neuroscience and Inhibrx.

_Daily Growth Insights